These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 8544674)

  • 41. Stroke in patients treated with thrombolytic therapy for acute myocardial infarction. The thrombosis in myocardial infarction clinical trial and a review of placebo-controlled trials.
    Price TR
    Stroke; 1990 Nov; 21(11 Suppl):III8-9. PubMed ID: 2122557
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Experience with the thrombolytic therapy of myocardial infarct].
    Gospodarenko AL; Ardashev VN; Tiurin VP; Chernetsov VA; Iakovlev VB; Vrublevskiĭ OIu; Makarenko AS; Sokolianskiĭ NV; Chernov SA; Kucherov VV; Davrent'eva TA
    Voen Med Zh; 1997 Nov; 318(11):40-5. PubMed ID: 9461835
    [No Abstract]   [Full Text] [Related]  

  • 43. [Platelet activation in the early phases of acute myocardial infarction].
    Salvioni A; Giraldi F; Assanelli E; Lauri G; Grazi M; Pardea S; Marenzi G
    Cardiologia; 1998 Aug; 43(8):825-32. PubMed ID: 9808873
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Is the use of t-PA as compared with streptokinase cost effective?
    Rose EA
    N Engl J Med; 1995 Oct; 333(15):1009; author reply 1010. PubMed ID: 7666904
    [No Abstract]   [Full Text] [Related]  

  • 45. Potential cost effectiveness of tissue plasminogen activator among patients previously treated with streptokinase.
    Massel D
    Can J Cardiol; 1999 Feb; 15(2):173-9. PubMed ID: 10079776
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Comparison of clinical efficacy of thrombolytic drugs in patients with acute myocardial infarction].
    López-Sendón JL
    Rev Esp Cardiol; 1992; 45 Suppl 2():9-20. PubMed ID: 1475514
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Decision support and the appropriate use of fibrinolysis in myocardial infarction.
    Kellett J
    Eff Clin Pract; 2001; 4(1):1-9. PubMed ID: 11234180
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group.
    Fagan SC; Morgenstern LB; Petitta A; Ward RE; Tilley BC; Marler JR; Levine SR; Broderick JP; Kwiatkowski TG; Frankel M; Brott TG; Walker MD
    Neurology; 1998 Apr; 50(4):883-90. PubMed ID: 9566367
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Medical therapy of acute myocardial infarction: Part I. Role of thrombolytic and antithrombotic therapy.
    Jafri SM; Walters BL; Borzak S
    J Intensive Care Med; 1995; 10(2):54-63. PubMed ID: 10172420
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Is the use of t-PA as compared with streptokinase cost effective?
    Armentano R; Favaloro RG
    N Engl J Med; 1995 Oct; 333(15):1009-10. PubMed ID: 7666905
    [No Abstract]   [Full Text] [Related]  

  • 51. Better patency with SK than with tPA?
    Peto R; Collins R
    J Am Coll Cardiol; 1999 Jan; 33(1):287-8. PubMed ID: 9935044
    [No Abstract]   [Full Text] [Related]  

  • 52. Comparison of tissue plasminogen activator and streptokinase in the management of acute myocardial infarction.
    White HD
    Chest; 1989 May; 95(5 Suppl):265S-269S. PubMed ID: 2495909
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The efficacy and safety of tissue plasminogen activator in acute ischemic strokes.
    Hoang KD; Rosen P
    J Emerg Med; 1992; 10(3):345-52. PubMed ID: 1624747
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Thrombolysis: state of the art.
    Sleight P
    Eur Heart J; 1993 Nov; 14 Suppl G():41-7. PubMed ID: 8287868
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Economic evaluation of treatment strategies for patients suffering acute myocardial infarction in Greece.
    Maniadakis N; Kaitelidou D; Siskou O; Spinthouri M; Liaropoulos L; Fragoulakis B; Hatzikou M; Alexopoulosi D
    Hellenic J Cardiol; 2005; 46(3):212-21. PubMed ID: 15981557
    [TBL] [Abstract][Full Text] [Related]  

  • 56. TPA: is it worth the price?
    Rich MW
    Am Heart J; 1987 Nov; 114(5):1259-61. PubMed ID: 3118691
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Improvement of regional myocardial metabolism after coronary thrombolysis induced with tissue-type plasminogen activator or streptokinase.
    Sobel BE; Geltman EM; Tiefenbrunn AJ; Jaffe AS; Spadaro JJ; Ter-Pogossian MM; Collen D; Ludbrook PA
    Circulation; 1984 May; 69(5):983-90. PubMed ID: 6608420
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Benefit-risk ratios in the assessment of the clinical evidence of a new therapy.
    Willan AR; O'Brien BJ; Cook DJ
    Control Clin Trials; 1997 Apr; 18(2):121-30. PubMed ID: 9129856
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Thrombolysis for stroke.
    Easton JD
    Cerebrovasc Dis; 1998; 8(4):191-7. PubMed ID: 9684057
    [No Abstract]   [Full Text] [Related]  

  • 60. Delivery of tissue plasminogen activator and streptokinase magnetic nanoparticles to target vascular diseases.
    Tadayon A; Jamshidi R; Esmaeili A
    Int J Pharm; 2015 Nov; 495(1):428-438. PubMed ID: 26363110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.